![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis and Safety Profile - oral presentation
|
|
|
Reported by Jules Levin
HIV Glasgow 2014 Nov 2-6
J Lalezari,1 C Brinson,2 GH Latiff,3 J Echevarría,4 M Thompson,5
S Trevino-Pérez,6 JR Bogner,7 D Stock,8 SR Joshi,8 GJ Hanna,9
M Lataillade8
for the AI438011 study team
1. Quest Clinical Research, San Francisco, CA, US; 2. Central Texas Clinical Research, Austin, TX, USA; 3. Maxwell Clinic, Durban, South Africa; 4. Hospital Nacional Cayetano Heredia, Lima, Peru;
5. AIDS Research Consortium of Atlanta, Atlanta, USA; 6. Mexico Centre for Clinical Research, Mexico City, Mexico; 7. Hospital of the University of Munich, Munich, Germany 8. Bristol-Myers Squibb, Wallingford, CT, USA; 9. Bristol-Myers Squibb, Princeton, NJ, USA
![Glasgow1.gif](../images/111814/111814-3/Glasgow1.gif)
![Glasgow2.gif](../images/111814/111814-3/Glasgow2.gif)
![Glasgow3.gif](../images/111814/111814-3/Glasgow3.gif)
![Glasgow4.gif](../images/111814/111814-3/Glasgow4.gif)
![Glasgow5.gif](../images/111814/111814-3/Glasgow5.gif)
![Glasgow6.gif](../images/111814/111814-3/Glasgow6.gif)
![Glasgow7.gif](../images/111814/111814-3/Glasgow7.gif)
![Glasgow8.gif](../images/111814/111814-3/Glasgow8.gif)
![Glasgow9.gif](../images/111814/111814-3/Glasgow9.gif)
![Glasgow10.gif](../images/111814/111814-3/Glasgow10.gif)
![Glasgow11.gif](../images/111814/111814-3/Glasgow11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|